Sêmeia announces a fundraising of 21 million euros from Acton Capital, XAnge via Mutuelles Impact, and Citizen Capital. Historical investors, including Banque des Territoires and Orange Ventures, are also participating in the operation.
Founded in 2017 in Toulouse by Mathieu Godart, Pierre Hornus and Daniel Szeftel, the startup is developing a medical remote monitoring platform intended for monitoring patients with chronic diseases. Its MedicWise digital medical device is now used in more than 500 healthcare establishments to monitor 35,000 patients.
The platform aggregates data from biological analysis laboratories, connected medical devices and even Health Insurance reimbursement histories. This data is analyzed in order to detect anomalies or worsenings between medical consultations. The alerts are then transmitted to the healthcare teams.
Sêmeia first developed in nephrology and transplantation before extending its activity to pulmonology, rheumatology, oncology and mental health. In 2022, the company had raised 8 million euros from Orange Ventures Impact, MH Innov’ and Banque des Territoires. It had also acquired its competitor Optim’Care in order to strengthen its position in the remote monitoring of chronic kidney diseases.
With this new operation, the company plans to extend remote monitoring to new medical specialties, to develop services based on artificial intelligence and to pursue its external growth strategy.
The market is evolving rapidly due to the aging of the population, the increase in chronic pathologies and the pressure placed on hospital systems. In this context, platforms capable of centralizing and exploiting longitudinal clinical data seek to become tools for coordinating care pathways. The integration of artificial intelligence now constitutes a central axis of the sector. The data collected as part of remote monitoring makes it possible to develop models intended to anticipate certain complications, prioritize alerts or automate part of the clinical monitoring.
